NCT05238649 - Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

January 28, 2023

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

BIOLOGICAL

SARS-Cov-2 Vaccine Inactivated

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Trial Locations (1)

Zhuhai Peoples' Hospital Medical Group, Zhuhai